HCV-associated nephropathy · KIMS Secunderabad
Hepatitis C-Associated Kidney Disease — How HCV Infection Damages the Kidneys
Hepatitis C virus (HCV) infection affects approximately 10 to 12 million people in India and is associated with a spectrum of extra-hepatic manifestations — conditions outside the liver caused by the systemic immune response to chronic HCV infection. Kidney disease is one of the most clinically significant extra-hepatic manifestations of HCV: approximately 10 to 20% of patients with chronic HCV infection develop some form of renal involvement during the course of their disease. The most important is HCV-associated cryoglobulinaemic glomerulonephritis — a vasculitic nephritis driven by cryoglobulin immune complexes.
The clinical importance of identifying HCV as the cause of kidney disease lies in the treatment revolution of the past decade. Direct-acting antiviral (DAA) therapy — sofosbuvir-based regimens with ledipasvir, velpatasvir, or daclatasvir — achieves sustained virological response (SVR — undetectable HCV RNA at 12 weeks after treatment) in over 95% of patients within 8 to 12 weeks of therapy. Curing the HCV infection eliminates the antigenic stimulus for cryoglobulin production and leads to sustained improvement or resolution of HCV-associated glomerulonephritis in the majority of patients who achieve SVR.
HCV kidney disease — three main patterns
Cryoglobulinaemic glomerulonephritis (the most common and most serious)
Chronic HCV infection drives a clonal B-cell expansion that produces cryoglobulins — immunoglobulins that precipitate at low temperatures. These cryoglobulin immune complexes deposit in the glomeruli, causing a type I membranoproliferative GN (MPGN) pattern on biopsy — mesangial expansion, endocapillary proliferation, and double contouring of the GBM. IF shows granular IgG and IgM deposits (IgM rheumatoid factor is a component of the cryoglobulin complex). The clinical presentation: haematuria, proteinuria, rapidly declining eGFR, hypertension, and — systemically — palpable purpura (lower limb vasculitis), peripheral neuropathy, and arthralgia. Complement C4 is typically very low (consumed by the classical pathway activation by the cryoglobulin complexes).
HCV-associated membranous nephropathy
Less common — HCV antigens and antibodies deposit in the subepithelial space of the GBM, causing a pattern resembling primary membranous nephropathy. Presents with nephrotic syndrome (heavy proteinuria, oedema, hypoalbuminaemia).
HCV-associated MPGN without cryoglobulinaemia
An immune complex MPGN driven by HCV antigen-antibody complexes but without detectable cryoglobulins. Similar biopsy appearance to cryoglobulinaemic GN but with less severe systemic vasculitic features.
Diagnosis at KIMS
HCV RNA (PCR) and HCV antibody — confirm active HCV infection. HCV RNA is essential — antibody alone does not confirm active viraemia.
Cryoglobulins — blood drawn warm (37°C) and processed at 37°C, then refrigerated for 7 days at 4°C to look for precipitate. A positive cryocrit confirms cryoglobulinaemia. Cryoglobulin typing (Type I = monoclonal; Type II = mixed with monoclonal rheumatoid factor; Type III = polyclonal) guides treatment intensity.
Complement C3 and C4 — low C4 (with normal or mildly low C3) is highly characteristic of cryoglobulinaemic GN. Persistent low C4 after HCV treatment indicates continued cryoglobulin activity.
Rheumatoid factor — elevated in Type II cryoglobulinaemia (the monoclonal IgM rheumatoid factor is the IgM component of the mixed cryoglobulin).
Kidney biopsy with LM + IF + EM at KIMS — establishes the specific GN pattern (MPGN, membranous, or other) and the degree of glomerular damage. IF shows the immune complex deposits. EM confirms the subendothelial location and may show characteristic 'fingerprint' deposits in cryoglobulinaemic GN.
Liver disease assessment — HCV-related liver fibrosis stage (FIB-4 score, fibroscan, or liver biopsy) determines whether DAA therapy is urgently needed and whether liver transplant may be required in the future.
Treatment
Direct-acting antiviral (DAA) therapy — the cornerstone
Sofosbuvir-velpatasvir (Epclusa) or sofosbuvir-ledipasvir — 12 weeks of oral therapy. SVR (cure of HCV) achieved in above 95%. After SVR: cryoglobulin levels fall progressively, complement C4 normalises, proteinuria and haematuria improve, and eGFR stabilises or improves in most patients. The improvement in kidney disease after DAA therapy may take 6 to 12 months to manifest fully.
Rituximab — for severe cryoglobulinaemic vasculitis or rapidly progressive GN
B-cell depletion with rituximab is used for severe acute cryoglobulinaemic nephritis causing rapidly declining eGFR, life-threatening purpuric vasculitis, or peripheral neuropathy. Rituximab depletes the B-cell clone producing the monoclonal rheumatoid factor, reducing cryoglobulin levels. DAA therapy is continued simultaneously and is essential for long-term remission.
Plasma exchange — for acute severe cryoglobulinaemic crisis
Removes circulating cryoglobulins rapidly in patients with acute renal failure, severe neuropathy, or critical skin ischaemia from vasculitis. A bridge to DAA and rituximab therapy.
HCV treatment is now available as highly affordable generic DAA therapy in India — sofosbuvir-based regimens cost dramatically less than the original branded medications. HCV cure does not require interferon injections (the old, side-effect-laden treatment). At KIMS, every HCV-positive patient with kidney involvement is assessed for DAA therapy regardless of fibrosis stage — kidney disease from HCV is a sufficient indication for treatment.
Book a Nephrology and Hepatitis C Assessment at KIMS. Call 040-4488-5000
Frequently Asked Questions — Hepatitis C Kidney Disease
Yes — untreated HCV-associated cryoglobulinaemic glomerulonephritis can cause progressive CKD and, in rapidly progressive cases, acute kidney failure requiring dialysis. The severity varies: some patients have mild, slowly progressive kidney involvement that remains stable for years; others develop a rapidly progressive nephritis with creatinine doubling in weeks. The development of CKD from HCV kidney disease is now largely preventable — DAA therapy curing the HCV infection resolves the antigenic stimulus for cryoglobulin production, leading to stabilisation or improvement of kidney function in the majority of patients who achieve SVR.
Cryoglobulins are immunoglobulins that reversibly precipitate at temperatures below body temperature — they are soluble at 37°C but form a gel or precipitate when cooled. In HCV infection, chronic B-cell stimulation by HCV antigens drives overproduction of a clonal IgM with rheumatoid factor activity — this IgM combines with HCV IgG antibodies to form mixed cryoglobulin complexes (Type II cryoglobulinaemia). These complexes circulate in the blood and deposit in small vessel walls — including the glomerular capillaries — activating complement and causing vasculitic inflammation. The same cryoglobulin complexes that cause glomerulonephritis also cause palpable purpura (skin vessel inflammation), peripheral neuropathy (nerve vessel inflammation), and arthralgia.
Yes — in the majority of patients. DAA therapy achieving SVR eliminates the antigenic stimulus for cryoglobulin production. After SVR: cryoglobulin levels fall progressively (usually by 50% within 6 months), complement C4 normalises over 6 to 12 months, proteinuria reduces, and eGFR stabilises or improves in 60 to 80% of patients. Complete resolution of cryoglobulinaemia takes 12 to 24 months after SVR. Patients with established significant glomerulosclerosis on biopsy recover less kidney function than those with predominantly cellular (inflammatory) changes. The earlier HCV is treated — before extensive renal scarring — the better the kidney outcome.
Yes — HCV-positive patients undergoing kidney transplantation require careful management both before and after transplant. DAA therapy before transplant significantly reduces the risk of HCV-related post-transplant complications (fibrosing cholestatic hepatitis — a devastating liver complication in immunosuppressed HCV-positive transplant recipients). Post-transplant HCV treatment with DAA is safe and effective. The KIMS transplant nephrology team includes HCV status in the pre-transplant evaluation and coordinates DAA therapy timing with the transplant team. Kidney transplant from HCV-positive donors to HCV-positive recipients (D+/R+) is an accepted practice with DAA treatment post-transplant.
KIMS Secunderabad — Dr. Aswini Dutt T (glomerular disease subspecialty), HCV RNA and cryoglobulin testing, complement C3 and C4, kidney biopsy with LM + IF + EM (fingerprint deposit identification), DAA therapy coordination, rituximab for severe cryoglobulinaemic vasculitis, plasma exchange for acute crisis, transplant evaluation for HCV-related ESRD. NABH and NABL accredited. Call 040-4488-5000.